ABLYNX ANNOUNCES WARRANT EXERCISE
30 April 2018 - 3:15PM
REGULATED INFORMATION
GHENT, Belgium,
30 April 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX]
today announced, in conformity with Title II of the Law of 2 May
2007 and the Royal Decree of 14 February 2008, that an additional
152,884 common shares have been issued by the Company in
exchange for €1,882,980.40 as the result of the exercise of
warrants.
As a result of this transaction,
Ablynx now has a share capital of €140.956.895,66 represented by a
total number of 75,406,551 shares, conferring a total number of
75,406,551 voting rights.
The current total number of
outstanding rights (warrants) to subscribe for not yet issued
securities conferring voting rights is 2,594,841 entitling their
holders to subscribe for a total number of 2,594,841 new shares,
conferring a total number of 2,594,841 voting rights.
The current total number of
outstanding convertible bonds is 983, which, on the basis of the
current conversion price of €12.6631, are convertible into
7,761,768 new shares, conferring a total number of 7,761,768 voting
rights.
About
Ablynx
Ablynx is a biopharmaceutical
company engaged in the development of Nanobodies, proprietary
therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with
some of the features of small-molecule drugs. Ablynx is dedicated
to creating new medicines which will make a real difference to
society. Today, the Company has more than 45 proprietary and
partnered programmes in development in various therapeutic areas
including inflammation, haematology, immuno-oncology, oncology and
respiratory disease. The Company has collaborations with multiple
pharmaceutical companies including AbbVie; Boehringer Ingelheim;
Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA;
Merck KGaA; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The
Company is headquartered in Ghent, Belgium. More information can be
found on www.ablynx.com.
On 29 January 2018, Sanofi made an
offer to acquire all of Ablynx's outstanding ordinary shares
(including shares represented by American Depository Shares (ADSs),
warrants and convertible bonds) at a price of €45 per share, which
represents an aggregate equity value of approximately €3.9 billion.
The proposed transaction was unanimously approved by both the
Sanofi and Ablynx Board of Directors. The offer is comprised of two
separate but concurrent tender offers: (i) a tender offer
under the laws of Belgium for all of the outstanding shares,
warrants and convertible bonds of Ablynx (the "Belgian Offer") and (ii) a tender offer under the
laws of the U.S. for all of the outstanding shares held by U.S.
holders and ADSs held by holders, wherever located (the "U.S. Offer"). The initial acceptance period of the
tender offers commenced on 4 April 2018 and will expire at 5:00
p.m. ET / 11:00 p.m. CET on 4 May 2018, subject to extension.
For more
information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: lies.vanneste@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media
relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
e: ablynx@consilium-comms.com
Joele Frank,
Wilkinson Brimmer Katcher
Dan Katcher or Joseph Sala
t: +1 212-355-4449
pdf version of the press
release
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Ablynx via Globenewswire
Ablynx NV (NASDAQ:ABLX)
Historical Stock Chart
From May 2024 to Jun 2024
Ablynx NV (NASDAQ:ABLX)
Historical Stock Chart
From Jun 2023 to Jun 2024